Js Pharmatechno Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -56.90%
- Profit Growth -69.91%
- Ebitda -57.37%
- Net Worth 26.78%
- Total Assets -39.64%
About Js Pharmatechno
Js Pharmatechno Private Limited (JPPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 August 2017 (Seven years and six months 10 days old ). Its registered office is in Rangareddy, Telangana, India.
The Company is engaged in the Machinery And Equipment Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Kambham Johnyesu and Matrapu Suvartha serve as directors at the Company.
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U31900TG2017PTC118944
- Company No.
118944
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Aug 2017
- Date of AGM
05 Oct 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Js Pharmatechno?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kambham Johnyesu  | Director | 17-Aug-2017 | Current |
| Matrapu Suvartha | Director | 17-Aug-2017 | Current |
Financial Performance of Js Pharmatechno.
Js Pharmatechno Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 56.9% decrease. The company also saw a substantial fall in profitability, with a 69.91% decrease in profit. The company's net worth Soared by an impressive increase of 26.78%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Js Pharmatechno?
In 2023, Js Pharmatechno had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Genevex Pharma Private LimitedKambham Johnyesu and Matrapu Suvartha are mutual person
Zionark Technologies Private LimitedKambham Johnyesu and Matrapu Suvartha are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Js Pharmatechno?
Js Pharmatechno has a workforce of 8 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Js Pharmatechno, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Js Pharmatechno's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.